Organogenesis Holdings Inc. (ORGO)

Market Cap	687.86M
Revenue (ttm)	465.22M
Net Income (ttm)	-9.23M
Shares Out	126.91M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	25.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,027,753
Open	5.28
Previous Close	5.28
Day's Range	5.15 - 5.44
52-Week Range	2.61 - 7.08
Beta	1.49
Analysts	Buy
Price Target	8.00 (+47.6%)
Earnings Date	Nov 6, 2025

About ORGO

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic fo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 869
• Stock Exchange: NASDAQ
• Ticker Symbol: ORGO
• Website: https://organogenesis.com

Analyst Summary

According to 3 analysts, the average rating for ORGO stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 47.60% from the latest price.

Price Target

$8.0

(47.60% upside)

Analyst Consensus: Buy